Search

Your search keyword '"Velde, C. J. H."' showing total 943 results
Start Over Author "Velde, C. J. H."
943 results on '"Velde, C. J. H."'

3. Molecular Imaging of the Tumor Stroma and Beyond

Author

Vuijk, F. A., primary, Houvast, R., additional, Baart, V. M., additional, Velde, C. J. H. van de, additional, Vahrmeijer, A. L., additional, Hilling, D. E., additional, Mieog, J. S. D., additional, Slingerland, M., additional, Geus-Oei, L. F. de, additional, Hawinkels, L. J. A. C., additional, and Sier, C. F. M., additional

Published
2021
Full Text
View/download PDF

8. What Is Cancer of the Rectum?

Author

Lange, M. M., Kraima, A. C., van de Velde, C. J. H., deRuiter, M. C., Valentini, Vincenzo, editor, Schmoll, Hans-Joachim, editor, and van de Velde, Cornelis J. H., editor

Published
2018
Full Text
View/download PDF

9. Effect of preoperative chemotherapy on the histopathological classification of gastric cancer

Author

Caspers, I. A., primary, Biesma, H. D., additional, Wiklund, K., additional, Pontén, F., additional, Lind, P., additional, Nordsmark, M., additional, Sikorska, K., additional, Meershoek-KleinKranenbarg, E., additional, Hartgrink, H. H., additional, van de Velde, C. J. H., additional, van Sandick, J. W., additional, Verheij, M., additional, Cats, A., additional, and van Grieken, N. C. T., additional

Published
2023
Full Text
View/download PDF

10. 89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study

Author

Linders, D. G. J., primary, Deken, M. M., additional, van Dam, M. A., additional, Wasser, M. N. J. M., additional, Voormolen, E. M. C., additional, Kroep, J. R., additional, van Dongen, G. A. M. S., additional, Vugts, D., additional, Oosterkamp, H. M., additional, Straver, M. E., additional, van de Velde, C. J. H., additional, Cohen, D., additional, Dibbets-Schneider, P., additional, van Velden, F. H. P., additional, Pereira Arias-Bouda, L. M., additional, Vahrmeijer, A. L., additional, Liefers, G. J., additional, de Geus-Oei, L. F., additional, and Hilling, D. E., additional

Published
2023
Full Text
View/download PDF

11. Mammatumoren

Author

van de Velde, C. J. H., van Asperen, C. J., van Diest, P. J., Elkhuizen, P. H. M., Linn, S. C., Zonderland, H. M., Liefers, G. J., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

12. Maagcarcinoom

Author

Cats, A., Verheij, M., van Grieken, N. C. T., van de Velde, C. J. H., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

13. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy

Author

de Groot, A. F., Blok, E. J., Charehbili, A., Engels, C. C., Smit, V. T. H. B. M., Dekker-Ensink, N. G., Putter, H., Meershoek-Klein Kranenbarg, E., van de Velde, C. J. H., Liefers, G. J., Nortier, J. W. R., Kuppen, P. J. K., van der Burg, S. H., and Kroep, J. R.

Published
2019
Full Text
View/download PDF

16. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Author

Dijkstra, E. A., Zwart, W. H., Nilsson, P. J., Putter, H., Roodvoets, A. G. H., Kranenbarg, E. Meershoek-Klein, Froedin, J. E., Nygren, Peter, ostergaard, L., Kersten, C., Verbiene, I., Cervantes, A., Hendriks, M. P., Capdevila, J., Edhemovic, I., van de Velde, C. J. H., Marijnen, C. A. M., van Etten, B., Hospers, G. A. P., Glimelius, Bengt, Dijkstra, E. A., Zwart, W. H., Nilsson, P. J., Putter, H., Roodvoets, A. G. H., Kranenbarg, E. Meershoek-Klein, Froedin, J. E., Nygren, Peter, ostergaard, L., Kersten, C., Verbiene, I., Cervantes, A., Hendriks, M. P., Capdevila, J., Edhemovic, I., van de Velde, C. J. H., Marijnen, C. A. M., van Etten, B., Hospers, G. A. P., and Glimelius, Bengt

Abstract

Background: Pre-operative chemoradiotherapy (CRT) rather than radiotherapy (RT) has resulted in fewer locoregional recurrences (LRRs), but no decrease in distant metastasis (DM) rate for patients with locally advanced rectal cancer (LARC). In many countries, patients receive post-operative chemotherapy (pCT) to improve oncological outcomes. We investigated the value of pCT after pre-operative CRT in the RAPIDO trial. Patients and methods: Patients were randomised between experimental (short-course RT, chemotherapy and surgery) and standard-of-care treatment (CRT, surgery and pCT depending on hospital policy). In this substudy, we compared curatively resected patients from the standard-of-care group who received pCT (pCT+ group) with those who did not (pCT- group). Subsequently, patients from the pCT+ group who received at least 75% of the prescribed chemotherapy cycles (pCT >75% group) were compared with patients who did not receive pCT (pCT-/- group). By propensity score stratification (PSS), we adjusted for the following unbalanced confounders: age, clinical extramural vascular invasion, distance to the anal verge, ypT stage, ypN stage, residual tumour, serious adverse event (SAE) and/or readmission within 6 weeks after surgery and SAE related to pre-operative CRT. Cumulative probability of disease-free survival (DFS), DM, LRR and overall survival (OS) was analysed by Cox regression. Results: In total, 396/452 patients had a curative resection. The number of patients in the pCT+, pCT >75%, pCT- and pCT-/- groups was 184, 112, 154 and 149, respectively. The PSS-adjusted analyses for all endpoints demonstrated hazard ratios between approximately 0.7 and 0.8 (pCT+ versus pCT-), and 0.5 and 0.8 (pCT >75% versus pCT-/-). However, all 95% confidence intervals included 1. Conclusions: These data suggest a benefit of pCT after pre-operative CRT for patients with high-risk LARC, with approximately 20%-25% improvement in DFS and OS and 20%-25% risk reductions in DM

Published
2023
Full Text
View/download PDF

17. Authors' reply-A sensitivity analysis of the RAPIDO clinical trial

Author

Dijkstra, E. A., Zwart, W. H., Putter, H., Marijnen, C. A. M., Nilsson, P. J., van de Velde, C. J. H., van Etten, B., Hospers, G. A. P., Glimelius, Bengt, Dijkstra, E. A., Zwart, W. H., Putter, H., Marijnen, C. A. M., Nilsson, P. J., van de Velde, C. J. H., van Etten, B., Hospers, G. A. P., and Glimelius, Bengt

Published
2023
Full Text
View/download PDF

18. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial

Author

Dijkstra, E A, Zwart, W H, Nilsson, P J, Putter, H, Roodvoets, A G H, Meershoek-Klein Kranenbarg, E, Frödin, J E, Nygren, P, Østergaard, L, Kersten, C, Verbiené, I, Cervantes, A, Hendriks, M P, Capdevila, J, Edhemovic, I, van de Velde, C J H, Marijnen, C A M, van Etten, B, Hospers, G A P, Glimelius, B, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
post-operative chemotherapy, Cancer Research, oncological outcomes, propensity score stratification, Neoadjuvant Therapy/methods, Rectal Neoplasms/drug therapy, Infant, Disease-Free Survival, Chemoradiotherapy/methods, adjuvant chemotherapy, Neoplasm Recurrence, Local/drug therapy, Oncology, locally advanced rectal cancer, Humans
Abstract

BACKGROUND: Pre-operative chemoradiotherapy (CRT) rather than radiotherapy (RT) has resulted in fewer locoregional recurrences (LRRs), but no decrease in distant metastasis (DM) rate for patients with locally advanced rectal cancer (LARC). In many countries, patients receive post-operative chemotherapy (pCT) to improve oncological outcomes. We investigated the value of pCT after pre-operative CRT in the RAPIDO trial.PATIENTS AND METHODS: Patients were randomised between experimental (short-course RT, chemotherapy and surgery) and standard-of-care treatment (CRT, surgery and pCT depending on hospital policy). In this substudy, we compared curatively resected patients from the standard-of-care group who received pCT (pCT+ group) with those who did not (pCT- group). Subsequently, patients from the pCT+ group who received at least 75% of the prescribed chemotherapy cycles (pCT ≥75% group) were compared with patients who did not receive pCT (pCT-/- group). By propensity score stratification (PSS), we adjusted for the following unbalanced confounders: age, clinical extramural vascular invasion, distance to the anal verge, ypT stage, ypN stage, residual tumour, serious adverse event (SAE) and/or readmission within 6 weeks after surgery and SAE related to pre-operative CRT. Cumulative probability of disease-free survival (DFS), DM, LRR and overall survival (OS) was analysed by Cox regression.RESULTS: In total, 396/452 patients had a curative resection. The number of patients in the pCT+, pCT >75%, pCT- and pCT-/- groups was 184, 112, 154 and 149, respectively. The PSS-adjusted analyses for all endpoints demonstrated hazard ratios between approximately 0.7 and 0.8 (pCT+ versus pCT-), and 0.5 and 0.8 (pCT ≥75% versus pCT-/-). However, all 95% confidence intervals included 1.CONCLUSIONS: These data suggest a benefit of pCT after pre-operative CRT for patients with high-risk LARC, with approximately 20%-25% improvement in DFS and OS and 20%-25% risk reductions in DM and LRR. Compliance with pCT additionally reduces or improves all endpoints by 10%-20%. However, differences are not statistically significant.

Published
2023
Full Text
View/download PDF

21. 89 Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.

Author

Linders, D. G. J., Deken, M. M., van Dam, M. A., Wasser, M. N. J. M., Voormolen, E. M. C., Kroep, J. R., van Dongen, G. A. M. S., Vugts, D., Oosterkamp, H. M., Straver, M. E., van de Velde, C. J. H., Cohen, D., Dibbets-Schneider, P., van Velden, F. H. P., Pereira Arias-Bouda, L. M., Vahrmeijer, A. L., Liefers, G. J., de Geus-Oei, L. F., and Hilling, D. E.

Subjects
BREAST tumor diagnosis, PILOT projects, TRASTUZUMAB, EPIDERMAL growth factor receptors, POSITRON emission tomography computed tomography, LYMPH nodes, TREATMENT effectiveness, DUCTAL carcinoma, BREAST cancer, QUALITATIVE research, CANCER patients, RESEARCH funding, COMBINED modality therapy, BREAST tumors
Abstract

Simple Summary: In breast cancer patients in whom tumor cells overexpress the protein human epidermal growth factor receptor 2 (HER2), HER2-targeted therapy is the mainstay of neoadjuvant therapy (NAT). Two thirds of these patients respond so well to HER2-targeted therapy that during microscopic analysis of the surgically resected tissue, it becomes apparent there are no vital tumor cells left, classified as complete responders. These patients might not have needed surgery. However, with current imaging techniques such as MRI, it remains difficult to preoperatively assess whether there is residual tumor after NAT or not, so all patients still undergo surgery. This study investigated if a HER2-targeted PET/CT scan can reliably assess the response to NAT. In six patients, a HER2-targeted PET/CT scan was acquired before and after NAT. Two out of six patients had residual tumor at microscopic analysis. Visual assessment of the PET/CT scans correctly predicted the response in 66.7% of cases. When the PET/CT signal in both the scan before and after NAT was quantified and (percentual) changes were calculated, there was a difference in the change of signal between patients with and without residual tumor. This difference, although not statistically significant due to the limited patient number in this study, suggests that quantitative assessment of HER2-targeted PET/CT can be used for accurate response evaluation after NAT. Background: Approximately 20% of invasive ductal breast malignancies are human epidermal growth factor receptor 2 (HER2)-positive. These patients receive neoadjuvant systemic therapy (NAT) including HER2-targeting therapies. Up to 65% of patients achieve a pathological complete response (pCR). These patients might not have needed surgery. However, accurate preoperative identification of a pCR remains challenging. A radiologic complete response (rCR) on MRI corresponds to a pCR in only 73% of patients. The current feasibility study investigates if HER2-targeted PET/CT-imaging using Zirconium-89 (89Zr)-radiolabeled trastuzumab can be used for more accurate NAT response evaluation. Methods: HER2-positive breast cancer patients scheduled to undergo NAT and subsequent surgery received a 89Zr-trastuzumab PET/CT both before (PET/CT-1) and after (PET/CT-2) NAT. Qualitative and quantitative response evaluation was performed. Results: Six patients were enrolled. All primary tumors could be identified on PET/CT-1. Four patients had a pCR and two a pathological partial response (pPR) in the primary tumor. Qualitative assessment of PET/CT resulted in an accuracy of 66.7%, compared to 83.3% of the standard-of-care MRI. Quantitative assessment showed a difference between the SUVR on PET/CT-1 and PET/CT-2 (ΔSUVR) in patients with a pPR and pCR of −48% and −90% (p = 0.133), respectively. The difference in tumor-to-blood ratio on PET/CT-1 and PET/CT-2 (ΔTBR) in patients with pPR and pCR was −79% and −94% (p = 0.133), respectively. Three patients had metastatic lymph nodes at diagnosis that were all identified on PET/CT-1. All three patients achieved a nodal pCR. Qualitative assessment of the lymph nodes with PET/CT resulted in an accuracy of 66.7%, compared to 50% of the MRI. Conclusions: NAT response evaluation using 89Zr-trastuzumab PET/CT is feasible. In the current study, qualitative assessment of the PET/CT images is not superior to standard-of-care MRI. Our results suggest that quantitative assessment of 89Zr-trastuzumab PET/CT has potential for a more accurate response evaluation of the primary tumor after NAT in HER2-positive breast cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial

Author

van Amelsfoort, R. M., Walraven, I., Kieffer, J., Jansen, E. P. M., Cats, A., van Grieken, N. C. T., Meershoek-Klein Kranenbarg, E., Putter, H., van Sandick, J. W., Sikorska, K., van de Velde, C. J. H., Aaronson, N. K., Verheij, M., Boot, H., Trip, A., van Coevorden, F., Vanhoutvin, S., Swellengrebel, H. A. M., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., van Laarhoven, H. W. M., Loosveld, O. J. L., ten Tije, A. J., Erdkamp, F. L. G., Warmerdam, F. A. R. M., van der Peet, D. L., Verheul, H. M. W., Portielje, J. E. A., Spillenaar Bilgen, E. J., Poleé, M. B., Geenen, M. M., Neelis, K. J., Slingerland, M., Jansen, R. L. H., van Spronsen, D. J., Tanis, B. C., van Hillegersberg, R., Koopman, M., den Boer, M. O., Creemers, G. J., van den Berg, H. P., Baars, A., Appels, M. I. E., Smit, J. M., Muller, E. W., de Boer, J., van Dijk, M. A., van der Gaast, A., Otten, J. M. M. B., Ceha, H. M., Radiotherapy, CCA - Cancer Treatment and Quality of Life, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Oncology, Pathology, Amsterdam Gastroenterology Endocrinology Metabolism, Internal medicine, CCA - Cancer Treatment and quality of life, Medical oncology, and Medical Oncology

Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Oncology, Stomach Neoplasms, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Surveys and Questionnaires, Quality of Life, Humans, Prognosis, Neoadjuvant Therapy
Abstract

Background: The evaluation of health-related quality of life (HRQoL) in clinical trials has become increasingly important because it addresses the impact of treatment from the patient’s perspective. The primary aim of this study was to investigate the effect of postoperative chemotherapy and chemoradiotherapy (CRT) after neoadjuvant chemotherapy and surgery with extended (D2) lymphadenectomy on HRQoL in the CRITICS trial. Second, we investigated the potential prognostic value of pretreatment HRQoL on event-free survival (EFS) and overall survival (OS). Patients and Methods: Patients in the CRITICS trial were asked to complete HRQoL questionnaires (EORTC Quality-of-Life Questionnaire-Core 30 and Quality-of-Life Questionnaire gastric cancer–specific module) at baseline, after preoperative chemotherapy, after surgery, after postoperative chemotherapy or CRT, and at 12 months follow-up. Patients with at least 1 evaluable questionnaire (645 of 788 randomized patients) were included in the HRQoL analyses. The predefined endpoints included dysphagia, pain, physical functioning, fatigue, and Quality-of-Life Questionnaire-Core 30 summary score. Linear mixed modeling was used to assess differences over time and at each time point. Associations of baseline HRQoL with EFS and OS were investigated using multivariate Cox proportional hazards analyses. Results: At completion of postoperative chemo(radio)therapy, the chemotherapy group had significantly better physical functioning (P=.02; Cohen’s effect size = 0.42) and less dysphagia (P=.01; Cohen’s effect size = 0.38) compared with the CRT group. At baseline, worse social functioning (hazard ratio [HR], 2.20; 95% CI, 1.36–3.55; P=.001), nausea (HR, 1.89; 95% CI, 1.39–2.56; PP=.007), and histologic subtype (diffuse vs intestinal: HR, 1.94; 95% CI, 1.42–2.67; PP=.003) were significantly associated with worse EFS and OS. Conclusions: In the CRITICS trial, the chemotherapy group had significantly better physical functioning and less dysphagia after postoperative treatment. HRQoL scales at baseline were significantly associated with EFS and OS.

Published
2022
Full Text
View/download PDF

32. Towards Gene Therapy for Colorectal Liver Metastases

Author

van der Eb, M. M., Hoeben, R. C., van de Velde, C. J. H., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Oldhafer, Karl J., editor, Lang, Hauke, editor, and Pichlmayr, Rudolf, editor

Published
1998
Full Text
View/download PDF

34. Isolated Hepatic Perfusion with Tumor Necrosis Factor α and Melphalan: Experimental Studies in Pigs and Phase I Data from Humans

Author

de Vries, M. R., Rinkes, I. H. Borel, van de Velde, C. J. H., Wiggers, T., Tollenaar, R. A. E. M., Kuppen, P. J. K., Vahrmeijer, A. L., Eggermont, A. M. M., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Oldhafer, Karl J., editor, Lang, Hauke, editor, and Pichlmayr, Rudolf, editor

Published
1998
Full Text
View/download PDF

40. Response

Author

van de Water, Willemien, Kiderlen, Mandy, Bastiaannet, Esther, Westendorp, Rudi G.J., van de Velde, C. J. H., de Craen, Anton j. M., and Liefers, Gerrit-Jan

Published
2014
Full Text
View/download PDF

41. Mucinous phenotype is associated with response to neoadjuvant chemotherapy in microsatellite instable resectable gastric cancer

Author

Biesma, H. D., Soeratram, A. T. T. D., Sikorska, K., Caspers, I. A., van Essen, H. F., Egthuijsen, J. M. P., Mookhoek, A., Hoek, D. M., Vos, W., van Laarhoven, H. W. M., Nordsmark, M., van der Peet, D. L., Warmerdam, F. A. R. M., Geenen, M. M., Loosveld, O. J. L., Portielje, J. E. A., Los, M., Kranenbarg, E. Meershoek-Klein, Hartgrink, H. H., van Sandick, J., van de Velde, C. J. H., Verheij, M., Cats, A., Ylstra, B., van Grieken, N. C. T., Pathology, Internal medicine, Surgery, Amsterdam Gastroenterology Endocrinology Metabolism, Radiation Oncology, and CCA - Cancer biology and immunology

Published
2021

44. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES†

Author

Speirs, V., Viale, G., Mousa, K., Palmieri, C., Reed, S. N., Nicholas, H., Cheang, M., Jassem, J., Lønning, P. E., Kalaitzaki, E., van de Velde, C. J. H., Rasmussen, B. B., Verhoeven, D. M., Shaaban, A. M., Bartlett, J. M. S., Bliss, J. M., Coombes, R. C., Jassem, J., Brociek, A., Pliszka, A., Andersen, J., Bruun Rasmussen, B., van de Velde, C., Meershoek, E., Paridaens, R., Delorge, A., Coates, A., Camler, R., Coombes, R.C., Mousa, K., Reed, S., Verhoeven, D., Herman, S., Visini, M., and Lonning, P.

Published
2015
Full Text
View/download PDF

47. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†

Author

Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, Å., van den Broek, C. B. M., Fokstuen, T., Gelderblom, H., Kapiteijn, E., Leer, J. W. H., Marijnen, C. A. M., Martijn, H., Meershoek-Klein Kranenbarg, E., Nagtegaal, I. D., Påhlman, L., Punt, C. J. A., Putter, H., Roodvoets, A. G. H., Rutten, H. J. T., Steup, W. H., Glimelius, B., and van de Velde, C. J. H.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results